Authors:
M. Figols /IPEN/, CNEN/SP Instituto de Pesquisas Energéticas e Nucleares São Paulo Brazil

Search for other papers by M. Figols in
Current site
Google Scholar
PubMed
Close
,
R. Gonçalves /IPEN/, CNEN/SP Instituto de Pesquisas Energéticas e Nucleares São Paulo Brazil

Search for other papers by R. Gonçalves in
Current site
Google Scholar
PubMed
Close
,
E. Muramoto /IPEN/, CNEN/SP Instituto de Pesquisas Energéticas e Nucleares São Paulo Brazil

Search for other papers by E. Muramoto in
Current site
Google Scholar
PubMed
Close
,
S. Sato /IPEN/, CNEN/SP Instituto de Pesquisas Energéticas e Nucleares São Paulo Brazil

Search for other papers by S. Sato in
Current site
Google Scholar
PubMed
Close
,
D. Freire Martinez Dirección General de Energia Nuclear Guatemala

Search for other papers by D. Freire Martinez in
Current site
Google Scholar
PubMed
Close
,
M. Colturato /IPEN/, CNEN/SP Instituto de Pesquisas Energéticas e Nucleares São Paulo Brazil

Search for other papers by M. Colturato in
Current site
Google Scholar
PubMed
Close
,
C. Gonçalves /IPEN/, CNEN/SP Instituto de Pesquisas Energéticas e Nucleares São Paulo Brazil

Search for other papers by C. Gonçalves in
Current site
Google Scholar
PubMed
Close
, and
J. Knust Universitätsklinikum Radiologisches Zentrum D-4300 Essen FRG

Search for other papers by J. Knust in
Current site
Google Scholar
PubMed
Close
Restricted access

Abstract  

The described labelling and purification preparation of N-isopropyl-p-131I-amphetamine /131I-IMP/ represents a fast and efficient method to obtain a compound that fulfils all criteria of purity for its in-vivo application. After isotope exchange and quality control131I-IMP could be obtained with radiochemical yields in the range between 68% and 78% with a radiochemical purity of 98–99%. As demonstrated in animal experiments the cerebral affinity of IMP offers a possibility for the diagnosis of brain diseases in clinical studies when the product is labelled with123I.

  • Collapse
  • Expand

To see the editorial board, please visit the website of Springer Nature.

Manuscript Submission: HERE

For subscription options, please visit the website of Springer Nature.

Journal of Radionalytical and Nuclear Chemistry
Language English
Size A4
Year of
Foundation
1968
Volumes
per Year
1
Issues
per Year
12
Founder Akadémiai Kiadó
Founder's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Publisher Akadémiai Kiadó
Springer Nature Switzerland AG
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
CH-6330 Cham, Switzerland Gewerbestrasse 11.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 0236-5731 (Print)
ISSN 1588-2780 (Online)